Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Remko Schotte"'
Autor:
Els Verdegaal, Hergen Spits, Remko Schotte, Martijn Kedde, Gemma Moiset, Hans Van Eenennaam, Pauline van Helden, Sjoerd van der Burg, Julien Villaudy, Wouter Pos, Daniel Go, Christien Fatmawati, Etsuko Yasuda, Madalina Cercel, Esmay Frankin, Susan van Hal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/db80a70a00dd4578b39f1f849964e0ec
Autor:
Annelies Jorritsma-Smit, Michel W J M Wouters, Bianca Heemskerk, Nienke van Rooij, Pia Kvistborg, John B A G Haanen, Joost H van den Berg, Raquel Gomez-Eerland, Samira Michels, Maaike van Zon, Renate de Boer, Noor A M Bakker, Marit M van Buuren, Hergen Spits, Remko Schotte, Henk Mallo, Matthias Karger, Joris A van der Hage, Loes M Pronk, Marnix H Geukes Foppen, Christian U Blank, Jos H Beijnen, Bastiaan Nuijen, Ton N Schumacher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Purpose Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.Experimental Ten patients were treated
Externí odkaz:
https://doaj.org/article/dcfa2791fafa4572a3dce6276ee8be68
Autor:
Julien Villaudy, Hergen Spits, S. E. van Hal-van Veen, Yvonne Claassen, Etsuko Yasuda, Lina Bartels, Madalina Cercel, Marijn A. Gillissen, Koen Wagner, Christien Fatmawati, Sophie E. Levie, Arjen Q. Bakker, Mette D. Hazenberg, Martijn Kedde, P. van Helden, Remko Schotte, G. de Jong, D. van de Berg, S.H. van der Burg, Els M. E. Verdegaal
Publikováno v:
Cancer immunology, immunotherapy, 70(6), 1569-1581. Springer Science and Business Media Deutschland GmbH
Cancer Immunology, Immunotherapy. SPRINGER
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy. SPRINGER
Cancer Immunology, Immunotherapy
Targeted cancer therapy with monoclonal antibodies has proven successful for different cancer types but is limited by the availability of suitable antibody targets. CD43s, a unique sialylated form of CD43 expressed by hematologic malignancies, is a r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dfe427f863db65bb706514800570b75
https://pure.amc.nl/en/publications/melanoma-cells-can-be-eliminated-by-sialylated-cd43--cd3-bispecific-t-cell-engager-formats-in-vitro-and-in-vivo(9f57d06a-6d38-4f3b-81cd-b7210005d696).html
https://pure.amc.nl/en/publications/melanoma-cells-can-be-eliminated-by-sialylated-cd43--cd3-bispecific-t-cell-engager-formats-in-vitro-and-in-vivo(9f57d06a-6d38-4f3b-81cd-b7210005d696).html
Autor:
Susan van Hal, Pauline M. van Helden, Els M. E. Verdegaal, Daniel Go, Martijn Kedde, Madalina Cercel, Hans van Eenennaam, Esmay Frankin, Etsuko Yasuda, Hergen Spits, Christien Fatmawati, Julien Villaudy, Sjoerd H. van der Burg, Wouter Pos, Gemma Moiset, Remko Schotte
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Adaptive immunity to cancer cells forms a crucial part of cancer immunotherapy. Recently, the importance of tumor B-cell signatures were shown to correlate with melanoma survival. We investigated whether tumor-targeting antibodies could be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbd04cbbc66a80ff7b13b96463d3ca9
https://doi.org/10.1136/jitc-2020-sitc2020.0721
https://doi.org/10.1136/jitc-2020-sitc2020.0721
Autor:
Anikó Szabó, Sjeng Horbach, Remko Schotte, Susan E. van Hal-van Veen, Madalina Cercel, Hans van Eenennaam, Anita W. Rijneveld, Dorien van de Berg, Mette D. Hazenberg, Wouter Pos, Yvonne Claassen, Etsuko Yasuda, Hergen Spits, Piet Gros, Christien Fatmawati, Julien Villaudy, Esmay Frankin, Greta de Jong, Sophie E. Levie, Daniel M Go, Martijn Kedde, Viviana Neviani
Publikováno v:
Blood. 136:41-42
Despite recent advances in treatment of B-acute lymphoblastic leukemia (B-ALL) there is still a need for novel targeted therapies. The tetraspanin CD9 is expressed in 60-80% of B-ALL and correlates with adverse prognosis. Recently, the mouse CD9 anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f64a67151140de54b55a6be48f6f3103
https://doi.org/10.1182/blood-2020-134088
https://doi.org/10.1182/blood-2020-134088
Autor:
Remko Schotte, Anita W. Rijneveld, H. van Eenennaam, Anikó Szabó, Sophie E. Levie, Etsuko Yasuda, Julien Villaudy, Hergen Spits, Martijn Kedde, S.H. van der Burg, Madalina Cercel, Viviana Neviani, Sjeng Horbach, Christien Fatmawati, G. de Jong, Wouter Pos, Piet Gros, P. van Helden, Mette D. Hazenberg, Els M. E. Verdegaal
Publikováno v:
Annals of Oncology. 31:S493
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d8cae01853ec6803156fa381ddea045
https://doi.org/10.1016/j.annonc.2020.08.696
https://doi.org/10.1016/j.annonc.2020.08.696
Autor:
Els M. E. Verdegaal, Remko Schotte, H. van Eenennaam, Madalina Cercel, Gemma Moiset, S.H. van der Burg, Wouter Pos, Christien Fatmawati, S. E. van Hal-van Veen, Etsuko Yasuda, Esmay Frankin, P. van Helden, Julien Villaudy, D. Go, Hergen Spits, Martijn Kedde, Koen Wagner
Publikováno v:
Annals of Oncology. 31:S492
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e71eb2f8245b6d7bb1717dba5b1c8e46
https://doi.org/10.1016/j.annonc.2020.08.694
https://doi.org/10.1016/j.annonc.2020.08.694
Autor:
Els M. E. Verdegaal, Piet Gros, Susan van Hal, Hans van Eenennaam, Hergen Spits, Julien Villaudy, Yvonne Claasen, Christien Fatmawati, Pauline M. van Helden, Viviana Neviani, Koen Wagner, Etsuko Yasuda, Martijn Kedde, Wouter Pos, Sjoerd H. van der Burg, Remko Schotte, Daniel Go
Publikováno v:
Cancer Research. 80:532-532
Background Adaptive immunity to cancer cells has been shown to form a crucial part of cancer immunotherapy. Recently, the importance of tumor B-cell signatures were shown to correlate with melanoma survival. We investigated whether anti-tumor antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50ba34083feeae1e975759e3cc6c00c3
https://doi.org/10.1158/1538-7445.am2020-532
https://doi.org/10.1158/1538-7445.am2020-532
Autor:
Mette D. Hazenberg, Hergen Spits, Anikó Szabó, Greta de Jong, Remko Schotte, Madalina Cercel, Hans van Eenennaam, Martijn Kedde, Etsuko Yasuda, Pauline M. van Helden, Els M. E. Verdegaal, Sjoerd H. van der Burg, Wouter Pos, Sophie E. Levie, Esmay Frankin, Julien Villaudy, Daniel Go, Susan van Hal, Anita van Rijneveld
Publikováno v:
Cancer Research. 80:531-531
Introduction Despite rapid advances in immunotherapeutic options for precursor B-acute lymphoblastic leukemia (BCP-ALL), outcomes remain poor especially for adult ALL and relapsed pediatric ALL. With conventional chemotherapy remission percentages in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9213a45f34c6c731cdb6ee85edcdb2f0
https://doi.org/10.1158/1538-7445.am2020-531
https://doi.org/10.1158/1538-7445.am2020-531
Autor:
Greta de Jong, Els M. E. Verdegaal, Lina Bartels, Koen Wagner, Christien Fatmawati, Susan E. van Hal-van Veen, Etsuko Yasuda, Mette D. Hazenberg, Arjen Q. Bakker, Dorien van de Berg, Hergen Spits, Martijn Kedde, Marijn A. Gillissen, Madalina Cercel, Remko Schotte, Pauline M. van Helden, Julien Villaudy, Yvonne Claassen, Sophie E. Levie
Publikováno v:
Cancer Research. 80:542-542
Introduction CD43s, a unique sialylated form of CD43 expressed by myeloid malignancies, is a novel target and AT1413, an antibody targeting CD43s was shown to have therapeutic potential against acute myeloid leukemia (AML) and myelodysplastic syndrom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::105840dd1c0989b590503049597d082f
https://doi.org/10.1158/1538-7445.am2020-542
https://doi.org/10.1158/1538-7445.am2020-542